Clinical Trial

Gemcitabine Plus Nab-paclitaxel as Switch Maintenance Versus Continuation of Modified FOLFIRINOX as 1st Line Chemotherapy in Patients With Advanced Pancreatic Cancer.

Study acronym: PANThEON
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
PANThEON is a randomized, open-label, multicenter phase III trial aimed at comparing the switch maintenance with gemcitabine plus nab-paclitaxel (ARM B) versus mFOLFIRINOX continuation (ARM A) in terms of overall survival (OS) in patients with unresectable LAD or mPDAC without disease progression following 3 months of induction mFOLFIRINOX triplet chemotherapy.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-03-20; most recent amendment 2025-05-23.
Trial Details
NCT Number NCT06897644
Lead Sponsor Gruppo Oncologico del Nord-Ovest
Collaborators: Rising Tide Foundation
Conditions Pancreatic Adenocarcinoma Advanced or Metastatic
Enrollment 340 participants
Start Date 2025-03-27
Primary Completion 2029-01-01 (estimated)
Study Completion 2030-01-01 (estimated)
Updated on ClinicalTrials.gov 2025-05-25